<p>CureVac（纳斯达克代码：CVAC - 获取免费报告）的股票在周五交易前出现了跳空上涨。该股票之前收于 3.26 美元，但开盘价为 3.37 美元。CureVac 的股票最后交易价格为 3.35 美元，成交量为 42,511 股。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>2 只小盘股将在牛市中大放异彩</li>
</ul>
<p>另外，JMP 证券在 2 月 14 日的研究报告中重申了对 CureVac 的 “市场表现优于大盘” 评级，并设定了 16.00 美元的目标价。</p>
<p><strong>查看我们关于 CVAC 的最新报告</strong></p>
<h2>CureVac 股票表现</h2>
<ul>
<li>3 只因 COVID 复苏而值得购买的股票</li>
</ul>
<p>该公司的市值为 7.6051 亿美元，市盈率为 6.15，贝塔系数为 2.48。该股票的 50 日移动平均价格为 3.04 美元，200 日移动平均价格为 3.17 美元。公司的债务股本比率为 0.05，速动比率为 6.19，流动比率为 6.20。</p>
<p>CureVac（纳斯达克代码：CVAC - 获取免费报告）最近于 4 月 10 日发布了季度财报。该公司报告每股收益（EPS）为-0.15 美元，低于市场共识预期的-0.14 美元，差距为 0.01 美元。CureVac 的净利润率为 20.72%，股本回报率为 21.98%。该公司在本季度的收入为 1544 万美元，而市场共识预期为 640 万美元。整体来看，研究分析师预计 CureVac 在当前财政年度将发布 0.72 美元的每股收益。</p>
<h2>对 CureVac 的对冲基金看法</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对该股票的持仓。Jane Street Group LLC 在第三季度将其在 CureVac 的持股比例提高了 239.0%。Jane Street Group LLC 目前拥有 79,247 股该公司的股票，价值 235,000 美元，此前在上个季度又购买了 55,867 股。巴克莱 PLC 在第三季度收购了 CureVac 的新股份，价值约 67,000 美元。中国泛海资产管理有限公司在第四季度将其在 CureVac 的持股提高了 10.3%。中国泛海资产管理有限公司目前拥有 47,568 股该公司的股票，价值 162,000 美元，此前在此期间又收购了 4,425 股。Signaturefd LLC 在第四季度将其在 CureVac 的持股增加了 29.2%。Signaturefd LLC 目前拥有 36,140 股该公司的股票，价值 123,000 美元，此前在上个季度又购买了 8,170 股。最后，Geode Capital Management LLC 在第四季度将其在 CureVac 的持股增加了 10.3%。Geode Capital Management LLC 目前拥有 241,750 股该公司的股票，价值 824,000 美元，此前在此期间又购买了 22,491 股。17.26% 的股票由机构投资者持有。</p>
<h2>CureVac 公司简介</h2>
<p>（获取免费报告）</p>
<p>CureVac N.V.是一家生物制药公司，专注于开发基于信使核糖核酸（mRNA）的各种变革性药物。它正在开发预防性疫苗，例如针对 SARS-CoV-2 的 mRNA 疫苗候选者 CV2CoV，目前处于第一阶段临床试验；CV7202 用于狂犬病治疗，亦处于第一阶段临床试验；以及用于治疗多价季节性流感的 CVSQIV；Flu SV mRNA 用于治疗核苷酸、单抗季节性流感。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 CureVac 更具吸引力</li>
<li>投资者需要了解即将上市的 IPO</li>
<li>空头最近放弃了这三只股票</li>
<li>内部交易可能不会告诉你你想知道的</li>
<li>今年表现优于市场的三只无聊股票</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>如果你想购买 AbbVie 但没有，现在仍然有机会购买</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 CureVac 吗？</h2>
<p>在考虑 CureVac 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CureVac 并不在名单上。</p>
<p>虽然 CureVac 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CVAC

<p>CureVac（纳斯达克代码：CVAC）股价在开盘前从 3.26 美元跳涨至 3.37 美元，最终收于 3.35 美元，成交量为 42,511 股。JMP Securities 维持 “市场表现优于大盘” 的评级，目标价为 16.00 美元。该公司报告的季度每股收益为（-0.15 美元），未达到预期，但收入为 1544 万美元，超出预期。CureVac 专注于基于 mRNA 的药物，市值为 7.6051 亿美元。机构投资者持有该股票的 17.26%，多家对冲基金的持股比例显著增加</p>

<p>Shares of CureVac (NASDAQ:CVAC - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $3.26, but opened at $3.37. CureVac shares last traded at $3.35, with a volume of 42,511 shares trading hands.</p>
<div class="lb-trans"><p>CureVac（纳斯达克代码：CVAC - 获取免费报告）的股票在周五交易前出现了跳空上涨。该股票之前收于 3.26 美元，但开盘价为 3.37 美元。CureVac 的股票最后交易价格为 3.35 美元，成交量为 42,511 股。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>2 Small-Cap Stocks Set to Shine in a Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只小盘股将在牛市中大放异彩</li>
</ul>
</div><p>Separately, JMP Securities reiterated a &#34;market outperform&#34; rating and set a $16.00 price objective on shares of CureVac in a research note on Friday, February 14th.</p>
<div class="lb-trans"><p>另外，JMP 证券在 2 月 14 日的研究报告中重申了对 CureVac 的 “市场表现优于大盘” 评级，并设定了 16.00 美元的目标价。</p>
</div><p><strong>View Our Latest Report on CVAC</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CVAC 的最新报告</strong></p>
</div><h2>CureVac Stock Performance</h2>
<div class="lb-trans"><h2>CureVac 股票表现</h2>
</div><ul>
<li>3 Stocks to Buy For the COVID Resurgence</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只因 COVID 复苏而值得购买的股票</li>
</ul>
</div><p>The company has a market capitalization of $760.51 million, a P/E ratio of 6.15 and a beta of 2.48. The stock's fifty day moving average price is $3.04 and its 200-day moving average price is $3.17. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20.</p>
<div class="lb-trans"><p>该公司的市值为 7.6051 亿美元，市盈率为 6.15，贝塔系数为 2.48。该股票的 50 日移动平均价格为 3.04 美元，200 日移动平均价格为 3.17 美元。公司的债务股本比率为 0.05，速动比率为 6.19，流动比率为 6.20。</p>
</div><p>CureVac (NASDAQ:CVAC - Get Free Report) last released its quarterly earnings data on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). CureVac had a net margin of 20.72% and a return on equity of 21.98%. The business had revenue of $15.44 million during the quarter, compared to the consensus estimate of $6.40 million. As a group, research analysts anticipate that CureVac will post 0.72 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CureVac（纳斯达克代码：CVAC - 获取免费报告）最近于 4 月 10 日发布了季度财报。该公司报告每股收益（EPS）为-0.15 美元，低于市场共识预期的-0.14 美元，差距为 0.01 美元。CureVac 的净利润率为 20.72%，股本回报率为 21.98%。该公司在本季度的收入为 1544 万美元，而市场共识预期为 640 万美元。整体来看，研究分析师预计 CureVac 在当前财政年度将发布 0.72 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On CureVac</h2>
<div class="lb-trans"><h2>对 CureVac 的对冲基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC lifted its stake in shares of CureVac by 239.0% during the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock worth $235,000 after buying an additional 55,867 shares during the last quarter. Barclays PLC acquired a new stake in CureVac during the third quarter worth approximately $67,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of CureVac by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company's stock worth $162,000 after acquiring an additional 4,425 shares during the period. Signaturefd LLC grew its position in shares of CureVac by 29.2% in the fourth quarter. Signaturefd LLC now owns 36,140 shares of the company's stock valued at $123,000 after purchasing an additional 8,170 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of CureVac by 10.3% during the fourth quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock worth $824,000 after purchasing an additional 22,491 shares during the period. 17.26% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该股票的持仓。Jane Street Group LLC 在第三季度将其在 CureVac 的持股比例提高了 239.0%。Jane Street Group LLC 目前拥有 79,247 股该公司的股票，价值 235,000 美元，此前在上个季度又购买了 55,867 股。巴克莱 PLC 在第三季度收购了 CureVac 的新股份，价值约 67,000 美元。中国泛海资产管理有限公司在第四季度将其在 CureVac 的持股提高了 10.3%。中国泛海资产管理有限公司目前拥有 47,568 股该公司的股票，价值 162,000 美元，此前在此期间又收购了 4,425 股。Signaturefd LLC 在第四季度将其在 CureVac 的持股增加了 29.2%。Signaturefd LLC 目前拥有 36,140 股该公司的股票，价值 123,000 美元，此前在上个季度又购买了 8,170 股。最后，Geode Capital Management LLC 在第四季度将其在 CureVac 的持股增加了 10.3%。Geode Capital Management LLC 目前拥有 241,750 股该公司的股票，价值 824,000 美元，此前在此期间又购买了 22,491 股。17.26% 的股票由机构投资者持有。</p>
</div><h2>CureVac Company Profile</h2>
<div class="lb-trans"><h2>CureVac 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.</p>
<div class="lb-trans"><p>CureVac N.V.是一家生物制药公司，专注于开发基于信使核糖核酸（mRNA）的各种变革性药物。它正在开发预防性疫苗，例如针对 SARS-CoV-2 的 mRNA 疫苗候选者 CV2CoV，目前处于第一阶段临床试验；CV7202 用于狂犬病治疗，亦处于第一阶段临床试验；以及用于治疗多价季节性流感的 CVSQIV；Flu SV mRNA 用于治疗核苷酸、单抗季节性流感。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than CureVac</li>
<li>What Investors Need to Know About Upcoming IPOs</li>
<li>Short Sellers Gave Up on These 3 Names Recently</li>
<li>Insider Trades May Not Tell You What You Think</li>
<li>3 Boring Stocks Outperforming the Market This Year</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 CureVac 更具吸引力</li>
<li>投资者需要了解即将上市的 IPO</li>
<li>空头最近放弃了这三只股票</li>
<li>内部交易可能不会告诉你你想知道的</li>
<li>今年表现优于市场的三只无聊股票</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>如果你想购买 AbbVie 但没有，现在仍然有机会购买</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CureVac Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 CureVac 吗？</h2>
</div><p>Before you consider CureVac, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CureVac 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CureVac 并不在名单上。</p>
</div><p>While CureVac currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CureVac 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

CureVac（纳斯达克股票代码：CVAC）股价跳空上涨的原因